Zacks Investment Research cut shares of EXACT Sciences (NASDAQ:EXAS) from a hold rating to a sell rating in a report published on Thursday morning, Zacks.com reports.

According to Zacks, “EXACT Sciences Corporation uses applied genomics to develop effective, patient-friendly screening technologies for use in the detection of cancer. Certain of its technologies have been licensed to Laboratory Corporation of America Holdings for a stool-based DNA screening assay for colorectal cancer in the average-risk population. Colorectal cancer, which is the most deadly cancer among non-smokers, is generally curable if detected early. Despite the availability of colorectal cancer screening and diagnostic tests for more than twenty years, the rate of early detection of colorectal cancer remains low, and deaths from colorectal cancer remain high. EXACT Sciences believes its genomics-based technologies would help to enable detection of colorectal cancer so that more people can be effectively treated. “

A number of other analysts have also weighed in on the stock. Jefferies Financial Group upped their target price on shares of EXACT Sciences from $100.00 to $115.00 and gave the stock a buy rating in a research note on Wednesday, May 1st. Canaccord Genuity upped their target price on shares of Ideagen from GBX 170 ($2.22) to GBX 180 ($2.35) and gave the stock a buy rating in a research note on Wednesday, July 17th. UBS Group lowered shares of Advanced Disposal Services from a buy rating to a neutral rating and set a $33.00 target price on the stock. in a research note on Wednesday, May 1st. They noted that the move was a valuation call. BTIG Research upped their target price on shares of Apple to $234.00 and gave the stock a buy rating in a research note on Wednesday, May 1st. Finally, BidaskClub lowered shares of Ames National from a hold rating to a sell rating in a research note on Wednesday, July 17th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and eleven have given a buy rating to the stock. EXACT Sciences presently has an average rating of Buy and a consensus target price of $109.82.

Shares of EXAS opened at $114.88 on Thursday. The firm has a market capitalization of $14.84 billion, a PE ratio of -84.47 and a beta of 1.65. EXACT Sciences has a 1 year low of $47.78 and a 1 year high of $121.98. The company has a debt-to-equity ratio of 1.02, a current ratio of 8.39 and a quick ratio of 8.13. The stock’s 50-day simple moving average is $113.12.

EXACT Sciences (NASDAQ:EXAS) last issued its quarterly earnings results on Tuesday, April 30th. The medical research company reported ($0.66) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.65) by ($0.01). EXACT Sciences had a negative return on equity of 28.83% and a negative net margin of 41.58%. The business had revenue of $162.00 million for the quarter, compared to analyst estimates of $153.07 million. During the same period in the prior year, the company posted ($0.33) EPS. The firm’s revenue for the quarter was up 79.4% compared to the same quarter last year. On average, equities research analysts forecast that EXACT Sciences will post -2.2 EPS for the current year.

A number of institutional investors have recently made changes to their positions in the business. Allstate Corp increased its stake in EXACT Sciences by 1.4% in the first quarter. Allstate Corp now owns 7,080 shares of the medical research company’s stock valued at $613,000 after purchasing an additional 97 shares during the last quarter. GABELLI & Co INVESTMENT ADVISERS INC. increased its stake in EXACT Sciences by 2.4% in the first quarter. GABELLI & Co INVESTMENT ADVISERS INC. now owns 4,250 shares of the medical research company’s stock valued at $368,000 after purchasing an additional 100 shares during the last quarter. Gofen & Glossberg LLC IL increased its stake in EXACT Sciences by 1.8% in the first quarter. Gofen & Glossberg LLC IL now owns 8,375 shares of the medical research company’s stock valued at $725,000 after purchasing an additional 150 shares during the last quarter. First Hawaiian Bank increased its stake in EXACT Sciences by 160.0% in the first quarter. First Hawaiian Bank now owns 325 shares of the medical research company’s stock valued at $28,000 after purchasing an additional 200 shares during the last quarter. Finally, YorkBridge Wealth Partners LLC increased its stake in EXACT Sciences by 40.0% in the second quarter. YorkBridge Wealth Partners LLC now owns 700 shares of the medical research company’s stock valued at $83,000 after purchasing an additional 200 shares during the last quarter. Institutional investors own 86.72% of the company’s stock.

EXACT Sciences Company Profile

Exact Sciences Corporation, a molecular diagnostics company, focuses on developing products for the early detection and prevention of various cancers in the United States. The company offers Cologuard, a non-invasive stool-based DNA screening test for the early detection of colorectal cancer and pre-cancer.

See Also: What Are Cryptocurrencies?

Get a free copy of the Zacks research report on EXACT Sciences (EXAS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for EXACT Sciences (NASDAQ:EXAS)

Receive News & Ratings for EXACT Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EXACT Sciences and related companies with MarketBeat.com's FREE daily email newsletter.